Johnson & Johnson Reports Q4 and Full-Year 2021 Results
New Brunswick, N.J. (January 25, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2021. “Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and health care providers” said Joaquin Duato, Chief Executive Officer. “Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond.” OVERALL F...
Source: Johnson and Johnson - January 25, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news

This Calgary couple is working to destigmatize cancer for Black Canadians
When Yinka Oladele’s husband was diagnosed with multiple myeloma in 2016, she automatically became his caregiver. But she struggled to find the information and resources she needed to navigate his diagnosis as a Black patient. (Source: CBC | Health)
Source: CBC | Health - January 24, 2022 Category: Consumer Health News Tags: News/Canada/Calgary Source Type: news

Dana-Farber Cancer Institute gets $40M donation from Scottrade founder
Dana-Farber Cancer Institute in Boston received a $40 million grant to support multiple myeloma research. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 7, 2022 Category: Biotechnology Authors: Diana Barr Source Type: news

Lab Notes: Penn Medicine's $14M NIH grant; NRx seeks designation for drug candidate
Philadelphia-area life sciences news this week includes updates on research on how to use CAR T-cell therapy to help kidney transplant patients, breakthrough therapy designation request for a drug candidate, and a drug for relapsed or refractory multiple myeloma patients. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 30, 2021 Category: Pharmaceuticals Authors: John George Source Type: news

Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
RARITAN, N.J., December 29, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of teclistamab for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is an investigational, off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3.“Despite all the gains that have been made in treating multiple myeloma, the unmet need still remains very high. Our relentless pursuit of tre...
Source: Johnson and Johnson - December 29, 2021 Category: Pharmaceuticals Tags: Latest News Source Type: news

CAR-T Cell Therapy for Multiple Myeloma May Lead to Parkinson-Like Symptoms CAR-T Cell Therapy for Multiple Myeloma May Lead to Parkinson-Like Symptoms
Researchers at Mount Sinai in New York have reported a previously unknown neurological side effect in a patient with multiple myeloma who received CAR-T cell therapy in a clinical trial.Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 16, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

COVID Vaccines Offer Only Some Protection for People With Myeloma
New research shows COVID-19 vaccines provide far less protection to people with multiple myeloma than to survivors of other types of cancer. (Source: WebMD Health)
Source: WebMD Health - December 15, 2021 Category: Consumer Health News Source Type: news

COVID Vaccines Offer Only Some Protection for People Battling Myeloma
WEDNESDAY, Dec. 15, 2021 -- COVID-19 vaccination provides far less protection to people with multiple myeloma than to survivors of other types of cancer, new research shows. The findings highlight the need for multiple myeloma patients“to be... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 15, 2021 Category: General Medicine Source Type: news

COVID Vaccines Offer Only Some Protection for People Battling Myeloma
Title: COVID Vaccines Offer Only Some Protection for People Battling MyelomaCategory: Health NewsCreated: 12/15/2021 12:00:00 AMLast Editorial Review: 12/15/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - December 15, 2021 Category: Cancer & Oncology Source Type: news

New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
The objective responsive rate observed in this study suggests a potential benefit for many patients with triple-class exposed disease with an off-the-shelf therapy.”As of September 2021, 165 patients were treated with teclistamab at the SC 1.5 mg/kg dose across both Phase 1 and Phase 2 of MajesTEC-1.1 The primary objectives of the MajesTEC-1 Phase 1 study (NCT03145181) were to identify the recommended SC RP2D (part 1) and characterize the safety and tolerability of teclistamab at the RP2D (part 2). The primary objective of the MajesTEC-1 Phase 2 study (NCT04557098) was to evaluate the efficacy of teclistamab at the R...
Source: Johnson and Johnson - December 13, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
ATLANTA, Ga., December 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy administered as a single infusion, in the treatment of patients with relapsed and/or refractory multiple myeloma. The data, featured as an oral presentation at the American Society of Hematology (ASH) 2021 Annual Meeting (Abstract #549) and selected as part of the Hi...
Source: Johnson and Johnson - December 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Isatuximab Added to RVd Boosts Response in New Myeloma Isatuximab Added to RVd Boosts Response in New Myeloma
The addition of the anti-CD38 antibody improved minimal residual disease rates at the end of induction, a marker for better outcomes following autologous stem cell transplant.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 12, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma
ATLANTA, Ga., December 11, 2021– The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab (NCT03399799). Talquetamab is the only investigational off-the-shelf T cell redirecting bispecific antibody in clinical development targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.[1] Results from the study show that no new safety signals were observed with longer follow-up.1 Heavily pretreated patients with multiple myeloma treated with talquetamab at the recommended subcutaneous (SC)...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Clinical and Real-World Data Support Use of DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma
ATLANTA, Ga., December 11, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with DARZALEX® (daratumumab)-based regimens may be able to achieve, including a potential survival benefit for DARZALEX® in combination with lenalidomide and dexamethasone (Rd). Updated data from the randomized Phase 2 GRIFFIN study in transplant-eligible patients and real-world evidence in transplant-ineligible patients were presented at the American Society of Hematology (ASH) 2021 Annual Meeting. Data from the GRIFFIN study will also b...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

US Oncology Research, The US Oncology Network and Ontada Announce Data Presentations across Areas of Critical Need at 2021 American Society of Hematology Annual Meeting and Exposition
THE WOODLANDS, Texas, Dec. 9, 2021 — Investigators from US Oncology Research, The US Oncology Network (The Network), and OntadaTM will share results from more than 30 studies exploring areas such as diffuse large B cell lymphoma, non-Hodgkin lymphoma, multiple myeloma and hematological adverse even... (Source: McKesson News)
Source: McKesson News - December 9, 2021 Category: Information Technology Source Type: news

FDA Approves Time-Saving Combo for R/r Multiple Myeloma FDA Approves Time-Saving Combo for R/r Multiple Myeloma
The US Food and Drug Administration this week approved daratumumab + hyaluronidase-fihj and carfilzomib plus dexamethasone – a combination that features quickly administered subcutaneous daratumumab.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves Darzalex Faspro, Kyprolis, and Dexamethasone for Multiple Myeloma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 1, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

GSK unveils Target the Future, a global, multi-year programme to help address key challenges affecting the multiple myeloma community
GlaxoSmithKline (GSK) plc today launched Target the Future, an international, multi-year initiative dedicated to advancing innovation and addressing key needs in the multiple myeloma community. The programme will provide education on progress in the field of multiple myeloma, identify key challenges the community faces, and facilitate solutions to help create a better future for patients, their caregivers and loved ones. (Source: World Pharma News)
Source: World Pharma News - December 1, 2021 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

Scientists identify new types of a blood cancer and potential targeted treatments
Mount Sinai researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for never-before-defined subtypes of a blood cancer called multiple myeloma. They also identified potential targeted treatments based on the findings, as reported in Science Advances in November. (Source: World Pharma News)
Source: World Pharma News - November 17, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

UCLA scientists make strides toward an ‘off-the-shelf’ immune cell therapy for cancer
Immunotherapies, which harness the body ’s natural defenses to combat disease, have revolutionized the treatment of aggressive and deadly cancers. But often, these therapies — especially those based on immune cells — must be tailored to the individual patient, costing valuable time and pushing their price into the hundreds of thousa nds of dollars.Now, in a study published in the journal Cell Reports Medicine, UCLA researchers report a critical step forward in the development of an “off-the-shelf” cancer immunotherapy using rare but powerful immune cells that could potentially be produced...
Source: UCLA Newsroom: Health Sciences - November 16, 2021 Category: Universities & Medical Training Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline du...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cellenkos raises $15M Series A for platform targeting treatments for autoimmune, inflammatory disases
Cellenkos was founded by Dr. Simrit Parmar, an associate professor in the lymphoma and myeloma department at M.D. Anderson Cancer Center. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 4, 2021 Category: American Health Authors: Chris Mathews Source Type: news

New Trials in Lymphoma and MM: Could Your Patient Benefit? New Trials in Lymphoma and MM: Could Your Patient Benefit?
Maybe one of your patients could benefit from the late-phase clinical trials that are currently recruiting patients with lymphoma and multiple myeloma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Geert Jan van Oldenborgh obituary
Dutch physicist who helped to identify the links between human-induced climate change and extreme weather disastersGeert Jan van Oldenborgh, who has died aged 59 of multiple myeloma, was co-founder and member of a team of scientists who identified — at speed and while politically a hot topic — the links between human-induced climate change and forest fires, heatwaves, drought, flood and other specific meteorological catastrophes.This is trickier than it sounds. Extreme events have always happened, and for decades most climate scientists were not willing to say that this or that flood or heatwave was directly po...
Source: Guardian Unlimited Science - November 2, 2021 Category: Science Authors: Tim Radford Tags: Climate science Netherlands Europe Physics Climate crisis Fossil fuels Canada Source Type: news

Janssen Announces Extension of U.S. FDA BLA PDUFA Date for BCMA CAR-T Ciltacabtagene Autoleucel
RARITAN, N.J., November 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date to February 28, 2022 for the ciltacabtagene autoleucel (cilta-cel) Biologics License Application (BLA). Cilta-cel is a B-cell maturation antigen (BCMA) CAR-T therapy that is being investigated for the treatment of adults with relapsed and/or refractory multiple myeloma. The FDA extended the PDUFA date to allow sufficient time to review information recently submitted by the company pertaining to an update...
Source: Johnson and Johnson - November 1, 2021 Category: Pharmaceuticals Tags: Latest News Source Type: news

Johnson & Johnson Hike 2021 Profit Forecast as COVID-19 Vaccine Sales Grow
Sales of the cancer treatment Darzalex helped Johnson & Johnson deliver better-than-expected third-quarter earnings, while COVID-19 fueled vaccine revenue and had more customers reaching for Tylenol. The world’s biggest maker of health care products hiked its 2021 earnings forecast after saying Tuesday that net income climbed 3% to $3.67 billion in the recently completed quarter. Sales of the company’s single-shot COVID-19 vaccine started to pick up in the quarter and nearly doubled what it brought in during the first half of 2021. J&J also said that sales of over-the-counter drugs, which do not need pr...
Source: TIME: Health - October 19, 2021 Category: Consumer Health News Authors: TOM MURPHY/AP Tags: Uncategorized biztech2030 Vaccines wire Source Type: news

Why vaccinated people dying from Covid-19 doesn't mean the vaccines are ineffective
Former US Secretary of State Colin Powell died on Monday of Covid-19 complications. His family announced that he was fully vaccinated. He was 84 years old, and had multiple myeloma, a blood cancer. (Source: CNN.com - Health)
Source: CNN.com - Health - October 19, 2021 Category: Consumer Health News Source Type: news

Myeloma may have made Colin Powell more vulnerable to dying of COVID-19 despite vaccination
Powell, who was fully vaccinated, had been treated for multiple myeloma before dying from COVID-19 complications. (Source: Reuters: Health)
Source: Reuters: Health - October 19, 2021 Category: Consumer Health News Source Type: news

Johnson & Johnson Reports Q3 2021 Results
New Brunswick, N.J. (October 19, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2021. “Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health,” said Alex Gorsky, Chairman and Chief Executive Officer. “In the face of evolving marketplace dynamics resulting from the effects of COVID-19 and other global trends, we have continued to demonstrate the responsiveness and agility required to meet the needs of ou...
Source: Johnson and Johnson - October 19, 2021 Category: Pharmaceuticals Tags: Financial Source Type: news

What Scientists Know About the Risk of Breakthrough Covid Deaths
Deaths among people who have been fully vaccinated remain rare, but older adults and those with compromised immune systems are at much higher risk. (Source: NYT Health)
Source: NYT Health - October 19, 2021 Category: Consumer Health News Authors: Emily Anthes Tags: your-feed-science Disease Rates Coronavirus (2019-nCoV) Vaccination and Immunization Cancer Multiple Myeloma Immune System Antibodies Multiple Myeloma Research Foundation Powell, Colin L your-feed-health Source Type: news

Cancer Patients With Poor Antibody Response to COVID-19 Vaccines Also...
Patients with the blood cancer multiple myeloma often mount a poor antibody response to COVID-19 vaccines. Mount Sinai researchers have now discovered that these patients also have a weak response...(PRWeb October 19, 2021)Read the full story at https://www.prweb.com/releases/cancer_patients_with_poor_antibody_response_to_covid_19_vaccines_also_lack_secondary_immune_response_study_shows/prweb18272203.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 19, 2021 Category: Pharmaceuticals Source Type: news

Doctors explain why fully vaccinated Colin Powell was at increased risk of death from COVID-19
Doctors say Colin Powell's age, his battle with multiple myeloma - a type of blood cancer - and Parkinson's contributed to his heightened risk of death from Covid despite being fully vaccinated. (Source: the Mail online | Health)
Source: the Mail online | Health - October 18, 2021 Category: Consumer Health News Source Type: news

What Is Multiple Myeloma Cancer and Is It Curable?
Colin Powell had a form of blood cancer that saps natural immunity and also undermines the effects of vaccines like the ones used against Covid-19. (Source: NYT Health)
Source: NYT Health - October 18, 2021 Category: Consumer Health News Authors: Gina Kolata Tags: Multiple Myeloma Bone Marrow Deaths (Fatalities) Immune System Blood Powell, Colin L Source Type: news

What Colin Powell ’s COVID-19 Death Says About the Current State of the Pandemic
The death of Colin Powell, an 84-year-old former four-star general who served as Chairman of the Joint Chiefs of Staff under U.S. President George H.W. Bush and Secretary of State under President George W. Bush and is perhaps best known for his role in bringing the U.S. into its second war in Iraq, is a high-profile reminder of a grim reality: COVID-19 is not just a pandemic of the unvaccinated, as current president Joe Biden likes to say, but a pandemic of the elderly, too. From early on in the pandemic, we’ve known the virus disproportionately kills older people, and the overall data make that pretty clear: About 5...
Source: TIME: Health - October 18, 2021 Category: Consumer Health News Authors: Alex Fitzpatrick Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Confusion over booster and third Covid vaccine could be putting patients in 'harm's way'
VULNERABLE patients could be slipping through the net ahead of a nasty winter as confusion mounts over the difference between the third Covid vaccine and the booster shot, warns blood cancer charity Myeloma UK. What are the differences between the two and why is the confusion posing a grave health risk to patients? (Source: Daily Express - Health)
Source: Daily Express - Health - October 8, 2021 Category: Consumer Health News Source Type: news

ClonoSEQ minimal residual disease testing in multiple myeloma patients saves costs in Germany
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2021 Category: Drugs & Pharmacology Source Type: news

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral present...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate can...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Sharing Mayo Clinic: "Divine design" gives multiple myeloma patient transplant, care at home
Ann Arneson describes her journey to Mayo Clinic as “divine design.” Ann — a retired teacher, a leader in her church and ministry, mother, grandmother, and line dance enthusiast — is Mayo Clinic’s first bone marrow transplant patient to recover at home thanks to the new advanced care at home program. “I know that people and circumstances are not by chance, but for a purpose — part of a bigger plan,” says Ann. A brush… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 5, 2021 Category: Databases & Libraries Source Type: news

Dr Reddy's launches cancer drug in Canada
"Our launch of Reddy-Lenalidomide represents our firm commitment to providing access to affordable medicines for Canada's Multiple Myeloma and Myelodysplastic Syndrome (MDS) patient population," Vinod Ramachandran, Vice President and General Manager, Dr. Reddy's Laboratories Canada said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 2, 2021 Category: Pharmaceuticals Source Type: news

Blood cancer symptoms: The sign when you sleep that could signal the deadly disease
THERE are myriad symptoms to look out for when detecting the early stages of blood cancer. These indications differ when determining the nature of blood cancer, whether it is lymphoma, leukaemia myeloma, MDS, MPN or any other classification. However, recent studies have discovered an emerging symptom to look out for during the night. (Source: Daily Express - Health)
Source: Daily Express - Health - August 31, 2021 Category: Consumer Health News Source Type: news

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma
SAN DIEGO, Aug. 30, 2021 -- (Healthcare Sales & Marketing Network) -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutic... Biopharmaceuticals, Oncology, FDA Poseida Therapeutics, multiple myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 30, 2021 Category: Pharmaceuticals Source Type: news

Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function
Chimeric antigen receptor (CAR)–modified T cell therapy is effective in treating lymphomas, leukemias, and multiple myeloma in which the tumor cells express high amounts of target antigen. However, achieving durable remission for these hematological malignancies and extending CAR T cell therapy to patients with solid tumors will require receptors that can recognize and eliminate tumor cells with a low density of target antigen. Although CARs were designed to mimic T cell receptor (TCR) signaling, TCRs are at least 100-fold more sensitive to antigen. To design a CAR with improved antigen sensitivity, we directly compa...
Source: Signal Transduction Knowledge Environment - August 24, 2021 Category: Science Authors: Salter, A. I., Rajan, A., Kennedy, J. J., Ivey, R. G., Shelby, S. A., Leung, I., Templeton, M. L., Muhunthan, V., Voillet, V., Sommermeyer, D., Whiteaker, J. R., Gottardo, R., Veatch, S. L., Paulovich, A. G., Riddell, S. R. Tags: STKE Research Articles Source Type: news

Different IV Bisphosphonates Tied to Similar Skeletal Event Rate Different IV Bisphosphonates Tied to Similar Skeletal Event Rate
The risk of recurrent skeletal-related events in patients with multiple myeloma is similar with IV bisphosphonate dosing schedules ranging from 4 weeks to longer than 12 weeks, a new study suggests.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - August 2, 2021 Category: Orthopaedics Tags: Hematology-Oncology News Source Type: news

Thousands of NHS patients with myeloma to be offered pill that blocks production of the blood cancer
The drug will be offered to patients shortly after diagnosis, doubling the average time the cancer takes to return, according to stunning new results from British medical trials. (Source: the Mail online | Health)
Source: the Mail online | Health - July 31, 2021 Category: Consumer Health News Source Type: news

FDA Warns of Higher Death Risk With Pepaxto in Multiple Myeloma FDA Warns of Higher Death Risk With Pepaxto in Multiple Myeloma
Following an accelerated approval earlier this year, analysis of data from an ongoing confirmatory trial has shown an increased risk of death with melphalan flufenamide (Pepaxto).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 28, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Racial Disparities Persist in Multiple Myeloma Care, Outcomes
Hispanics have higher MM - related in - hospital mortality; recent decline seen in in - hospital mortality for all except NH - Blacks (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 26, 2021 Category: Cancer & Oncology Tags: Oncology, Journal, Source Type: news

Racial Disparities Persist in Multiple Myeloma Care, Outcomes
MONDAY, July 26, 2021 -- There are persistent disparities in multiple myeloma (MM) care for non-Hispanic (NH)-Blacks and Hispanics compared with NH-Whites, according to a study published online July 18 in Leukemia& Lymphoma. Samer Al Hadidi,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 26, 2021 Category: Pharmaceuticals Source Type: news

Risk for Psoriasis Increased for Cancer Survivors
Increased risks seen for survivors of leukemia, lymphoma, multiple myeloma, skin cancer, and lung cancer in subgroup analyses (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 21, 2021 Category: Cancer & Oncology Tags: Dermatology, Internal Medicine, Oncology, Journal, Source Type: news